MedTrace Logo

Defining, Recognising and Escalating Maternal Early Deterioration (DREaMED)

NCT06560931 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 459160

Last updated 2024-08-29

No results posted yet for this study

Summary

Every year more than 700,000 women give birth in the United Kingdom. Of these at least 8700 nearly die - called a "near-miss", and 70 die. Many more women suffer harm, often with effects lasting for life. Women from less wealthy areas and particular ethnic groups are more likely to come to harm.

"Vital signs" include measurements of blood pressure, heart and breathing rates. Doctors and midwives use tools that score vital signs to spot women becoming unwell. These tools are called "Modified Obstetric Early Warning Scores" (MOEWS). Despite their use, poor outcomes still occur. This may be because MOEWS use only the most recent vital signs. Using extra data like blood tests may help spot unwell people earlier.

The study aims to reduce poor outcomes for women giving birth. The study will find better ways of describing, spotting, and treating women becoming unwell.

The study have planned four linked projects to develop an electronic advanced maternal obstetric early warning system (eMOEWS). Patient and Public (PPIE) collaborators have developed this work with CI's. The study work closely with them throughout this project.

Once the study has completed these four projects, they plan to carry out a trial to assess whether the new eMOEWS leads to better outcomes than the existing tools.

Conditions

  • Pregnancy Complications
  • Pregnancy, High Risk

Sponsors & Collaborators

  • NHS England

    collaborator OTHER_GOV

  • Guy's and St Thomas' NHS Foundation Trust

    collaborator OTHER

  • King's College London

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Peter Watkinson · University of Oxford

  • Marian Knight · University of Oxford

Eligibility

Min Age
16 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-02
Primary Completion
2029-05-01
Completion
2029-05-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06560931 on ClinicalTrials.gov